Poulin Patrick, Theil Frank-Peter
Non-Clinical Development-Drug Safety, Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.
J Pharm Sci. 2002 Jan;91(1):129-56. doi: 10.1002/jps.10005.
In drug discovery and nonclinical development the volume of distribution at steady state (V(ss)) of each novel drug candidate is commonly determined under in vivo conditions. Therefore, it is of interest to predict V(ss) without conducting in vivo studies. The traditional description of V(ss) corresponds to the sum of the products of each tissue:plasma partition coefficient (P(t:p)) and the respective tissue volume in addition to the plasma volume. Because data on volumes of tissues and plasma are available in the literature for mammals, the other input parameters needed to estimate V(ss) are the P(t:p)'s, which can potentially be predicted with established tissue composition-based equations. In vitro data on drug lipophilicity and plasma protein binding are the input parameters used in these equations. Such a mechanism-based approach would be particularly useful to provide first-cut estimates of V(ss) prior to any in vivo studies and to explore potential unexpected deviations between sets of predicted and in vivo V(ss) data, when the in vivo data become available during the drug development process. The objective of the present study was to use tissue composition-based equations to predict rat and human V(ss) prior to in vivo studies for 123 structurally unrelated compounds (acids, bases, and neutrals). The predicted data were compared with in vivo data obtained from the literature or at Roche. Overall, the average ratio of predicted-to-experimental rat and human V(ss) values was 1.06 (SD = 0.817, r = 0.78, n = 147). In fact, 80% of all predicted values were within a factor of two of the corresponding experimental values. The drugs can therefore be separated into two groups. The first group contains 98 drugs for which the predicted V(ss) were within a factor of two of those experimentally determined (average ratio of 1.01, SD = 0.39, r = 0.93, n = 118), and the second group includes 25 other drugs for which the predicted and experimental V(ss) differ by a factor larger than two (average ratio of 1.32, SD = 1.74, r = 0.42, n = 29). Thus, additional relevant distribution processes were neglected in predicting V(ss) of drugs of the second group. This was true especially in the case of some cationic-amphiphilic bases. The present study is the first attempt to develop and validate a mechanistic distribution model for predicting rat and human V(ss) of drugs prior to in vivo studies.
在药物发现和非临床开发中,通常在体内条件下测定每个新型候选药物的稳态分布容积(V(ss))。因此,在不进行体内研究的情况下预测V(ss)具有重要意义。V(ss)的传统描述对应于每个组织:血浆分配系数(P(t:p))与相应组织容积的乘积之和,再加上血浆容积。由于哺乳动物组织和血浆容积的数据在文献中已有报道,估计V(ss)所需的其他输入参数是P(t:p),其有可能通过已建立的基于组织组成的方程进行预测。药物亲脂性和血浆蛋白结合的体外数据是这些方程中使用的输入参数。这种基于机制的方法在任何体内研究之前提供V(ss)的初步估计,并在药物开发过程中获得体内数据时,探索预测的和体内V(ss)数据集之间潜在的意外偏差,将特别有用。本研究的目的是在对123种结构不相关的化合物(酸、碱和中性化合物)进行体内研究之前,使用基于组织组成的方程预测大鼠和人类的V(ss)。将预测数据与从文献或罗氏公司获得的体内数据进行比较。总体而言,预测的大鼠和人类V(ss)值与实验值的平均比值为1.06(标准差=0.817,r=0.78,n=147)。事实上,所有预测值的80%在相应实验值的两倍范围内。因此,这些药物可分为两组。第一组包含98种药物,其预测的V(ss)在实验测定值的两倍范围内(平均比值为1.01,标准差=0.39,r=0.93,n=118),第二组包括25种其他药物,其预测的和实验的V(ss)相差超过两倍(平均比值为1.32,标准差=1.74,r=0.42,n=29)。因此,在预测第二组药物的V(ss)时忽略了其他相关的分布过程。在某些阳离子两亲性碱的情况下尤其如此。本研究是在体内研究之前开发和验证用于预测大鼠和人类药物V(ss)的机制性分布模型的首次尝试。